Fiche traitement
5-FU
Merck Sharp & Dohme LLC • Parkinson
Suivi actif
Phase 3
Résumé
5-FU est développé par Merck Sharp & Dohme LLC. Le traitement est actuellement en Phase 3. Il est associé à Parkinson. Son objectif thérapeutique principal est Ralentissement de la progression. Le statut actuel est : suivi actif.
À vérifier
Ralentissement de la progression
Phase 3
Merck Sharp & Dohme LLC
United States, Australia, Brazil, Chile, China, France, Germany, Guatemala, …
The irinotecan and cisplatin combination showed significant anti-tumor activity. In the first-line setting, the investigators showed that this regimen had significant anti-tumor activity in 47% of chemo-naïve NSCLC patients with 1-year survival rate of 64.2%. Again, the investigators showed that the second-line Irinotecan and cisplatin is an active and well-tolerated regimen in patients with advanced NSCLC pretreated with non-platinum based chemotherapy.
TS-1 (Jeil Pharmaceutical Co.,Ltd, Seoul, Korea) is an oral anticancer drug comprised of tegafur, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug that generates 5-fluorouracil (5-FU) in blood via metabolism by liver enzyme, and 5-chloro-2, 4-dihydroxypyridine enhance the serum concentration of 5-FU by the competitive inhibition of dihydropyrimidine dehydrogenase, an enzyme responsible for 5-FU catabolism. Potassium oxonate is also a reversible competitive inhibitor of orotate phosphoribosyl transferase, a phosphoenzyme for 5-FU. Diarrhea induced by 5-FU administration is though to be attributable to the phosphorylation of 5-FU by the enzyme in the gastrointestinal tissue. After oral administration of potassium oxonate, the concentration of potassium in the gastrointestinal tissue is high enough to inhibit the enzyme while the concentration in blood and tumor is reported to be either slight or nil. Because of these mechanism, oral TS-1 administration generates a higher concentration of 5-FU than protracted intravenous infusion of 5-FU given in a dose equimolar to the tegafur in S-1, whereas the incidence of adverse events concerning the GI tract does not increase. In a phase II trial of TS-1 as first-line setting in NSCLC, the response rate was 22% and the median survival time was 10.2 months. As expected, the incidence of severe gastrointestinal adverse events was low, and so was few severe hematologic toxicity. Recently 3-weekly TS-1 plus cisplatin showed activity against NSCLC with a response rate of 32.7% and the safety was acceptable.
2026-08-18
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
Phase 3
Début phase actuelle
Non disponible dans les sources synchronisées
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé
Objectif scientifique de l’étude
classification automatique vérifiable
Ralentissement de la progression
Confiance automatique : 66%
Ce pourcentage n’est pas une probabilité de succès clinique.
Il mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Indices détectés : progression → Ralentissement de la progression
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Description affichée depuis l’essai compatible NCT00874328, afin d’éviter le mélange entre plusieurs indications d’une même molécule.
Aucune incohérence majeure détectée entre la maladie, l’objectif et la description.
Transparence et qualité de la fiche
données vérifiablesClassificationCohérente automatiquement
Confiance de la fiche100 %
Source principaleSource officielle ou publication indexée
Dernière vérification2026-08-18
Anomalies détectées0
Validation humaineValidation humaine non effectuée
Donnée issue d’une source
Donnée normalisée automatiquement
Interprétation algorithmique
Classification scientifique multi-axes
ne pas confondre statut et résultatÉtat de l’étudeStatut inconnu
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable
Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifPhase enregistréePhase 3
Études associées1
Publications associées16
Statut consolidéSuivi actif
Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
20 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2008-10-01 | Début de l’étudeNCT00874328 | Registre d’essai clinique |
| 2012-12-01 | Fin de l’étude prévue / enregistréeNCT00874328 | Registre d’essai clinique |
| 2026-07-08 | PublicationChitosan/β-cyclodextrin nanocarriers enhance 5-fluorouracil efficacy against colorectal cancer via pH-responsive release and apoptosis modulation. | Scientific reports |
| 2026-07-10 | PublicationNetwork-level reprogramming of cell death pathways in colorectal cancer cells by combined thymoquinone and 5-fluorouracil treatment. | Frontiers in molecular biosciences |
| 2026-07-12 | PublicationPDLIM4 increases sphingolipid accumulation to promote cancer stem cell characteristics and chemotherapy resistance in colorectal cancer. | Communications biology |
| 2026-07-22 | Publication[Selective effectiveness of galactose-containing liposome IL-2 on liver lymphocytes]. | Gan to kagaku ryoho. Cancer & chemotherapy |
| 2026-08-08 | Création de l’enregistrementNCT00874328 | Registre d’essai clinique |
| 2026-08-08 | PublicationEffect of salt-induced structural changes in hydroxypropyl methylcellulose gels on 5-fluorouracil release. | International journal of biological macromolecules |
| 2026-08-08 | PublicationProtection of Fulvic Acid Against 5-Fluorouracil-induced Intestinal Injury in Mice. | Current pharmaceutical biotechnology |
| 2026-08-13 | PublicationBetulin Alleviates 5-Fluorouracil-Induced Intestinal Mucositis in Mice. | Nutrients |
| 2026-08-13 | PublicationResveratrol Modulates Phosphatidylcholine Metabolism-Related Enzymes and Enhances Chemosensitivity in Colorectal Cancer Models. | International journal of molecular sciences |
| 2026-08-13 | PublicationStem Cell-Delivered Cytosine Deaminase/5-Fluorocytosine and TRAIL Gene Therapy for Castration-Resistant Prostate Cancer: Translational Synthesis and First-in-Human Trial Concept. | International journal of molecular sciences |
| 2026-08-16 | PublicationSingle-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year Retrospective Audit. | Cureus |
| 2026-08-16 | PublicationComparative efficacy of intralesional therapies for keloid scars: a network meta-analysis. | Annals of medicine |
| 2026-08-16 | PublicationIdentification of fidelity-determined residues of Porcine reproductive and respiratory syndrome virus through structural alignment. | Virulence |
| 2026-08-16 | PublicationExosome-like nanoparticles derived from co-decoction enhance oral bioavailability and provide synergistic efficacy and reduced toxicity in combination with 5-fluorouracil for lung cancer therapy. | International journal of pharmaceutics: X |
| 2026-08-16 | PublicationDomain-specific cognitive impairments following oxaliplatin and 5-fluorouracil treatment in rats: A preclinical study. | Behavioural brain research |
| 2026-08-16 | PublicationPhytochemical basis and mechanistic insight of Swertia macrosperma in treating 5-fluorouracil-induced diarrhea. | Journal of ethnopharmacology |
| 2026-08-16 | PublicationMuribaculum as a microbial contributor of rifaximin-induced mucosal protection during chemotherapy. | Gut microbes |
| 2026-08-18 | Dernière mise à jour des données5-FU | Biomedical Watch |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
1 essai(s)
Début phase actuelle
Non disponible dans les sources synchronisées
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT00874328 | A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | Phase 1 | UNKNOWN | South Korea | National Cancer Center, Korea |
Publications liées
16 publication(s)Publications liées
16 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| Single-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year Retrospective Audit. Voir source | 42291898 | 10.7759/cureus.108823 | Cureus | |
| Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis. Voir source | 41860092 | 10.1080/07853890.2026.2619295 | Annals of medicine | |
| Identification of fidelity-determined residues of Porcine reproductive and respiratory syndrome virus through structural alignment. Voir source | 41649343 | 10.1080/21505594.2026.2629134 | Virulence | |
| Exosome-like nanoparticles derived from co-decoction enhance oral bioavailability and provide synergistic efficacy and reduced toxicity in combination with 5-fluorouracil for lung cancer therapy. Voir source | 42495154 | 10.1016/j.ijpx.2026.100611 | International journal of pharmaceutics: X | |
| Domain-specific cognitive impairments following oxaliplatin and 5-fluorouracil treatment in rats: A preclinical study. Voir source | 42336324 | 10.1016/j.bbr.2026.116331 | Behavioural brain research | |
| Phytochemical basis and mechanistic insight of Swertia macrosperma in treating 5-fluorouracil-induced diarrhea. Voir source | 42409345 | 10.1016/j.jep.2026.122163 | Journal of ethnopharmacology | |
| Muribaculum as a microbial contributor of rifaximin-induced mucosal protection during chemotherapy. Voir source | 42286866 | 10.1080/19490976.2026.2685994 | Gut microbes | |
| Betulin Alleviates 5-Fluorouracil-Induced Intestinal Mucositis in Mice. Voir source | 42588111 | 10.3390/nu18152487 | Nutrients | |
| Resveratrol Modulates Phosphatidylcholine Metabolism-Related Enzymes and Enhances Chemosensitivity in Colorectal Cancer Models. Voir source | 42589348 | 10.3390/ijms27156691 | International journal of molecular sciences | |
| Stem Cell-Delivered Cytosine Deaminase/5-Fluorocytosine and TRAIL Gene Therapy for Castration-Resistant Prostate Cancer: Translational Synthesis and First-in-Human Trial Concept. Voir source | 42589524 | 10.3390/ijms27156870 | International journal of molecular sciences | |
| Effect of salt-induced structural changes in hydroxypropyl methylcellulose gels on 5-fluorouracil release. Voir source | 42562258 | 10.1016/j.ijbiomac.2026.153904 | International journal of biological macromolecules | |
| Protection of Fulvic Acid Against 5-Fluorouracil-induced Intestinal Injury in Mice. Voir source | 42565411 | 10.2174/0113892010473841260716112008 | Current pharmaceutical biotechnology | |
| [Selective effectiveness of galactose-containing liposome IL-2 on liver lymphocytes]. Voir source | 7944413 | Gan to kagaku ryoho. Cancer & chemotherapy | ||
| PDLIM4 increases sphingolipid accumulation to promote cancer stem cell characteristics and chemotherapy resistance in colorectal cancer. Voir source | 42436219 | 10.1038/s42003-026-10627-9 | Communications biology | |
| Network-level reprogramming of cell death pathways in colorectal cancer cells by combined thymoquinone and 5-fluorouracil treatment. Voir source | 42422877 | 10.3389/fmolb.2026.1864680 | Frontiers in molecular biosciences | |
| Chitosan/β-cyclodextrin nanocarriers enhance 5-fluorouracil efficacy against colorectal cancer via pH-responsive release and apoptosis modulation. Voir source | 42414363 | 10.1038/s41598-026-60468-z | Scientific reports |
Sources officielles
liens de rechercheDernière mise à jour des données : 2026-08-18
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.